← Leaderboards
Soon Seog Jeong
Human Cell Co
$4,057,357
Attributed
$4,057,357
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,057,357 · 7
By mechanism
R43$2,084,777 · 6
R44$1,972,580 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsCost EffectiveFda ApprovedRecombinantsEscherichia ColiPreventBindingNeurotrophic Tyrosine Kinase Receptor Type 1Retinal Ganglion CellsSerumModificationGlaucomaMediatingRattusNerve Growth FactorsInnovationAttenuatedSafetyCellsEyedropsProductionClinical TrialsNgfr ProteinEfficacy Validation
Grant awards (8)
Optimizing NGF for Topical Treatment of Glaucoma$991,520
R44 · FY2024 · EY · contact PI
Topical treatment of an optimized NGF for Dry Eye$365,000
R43 · FY2024 · EY · contact PI
Topical NGF Therapy and oral nicotinamide supplementation for Glaucoma$360,897
R43 · FY2024 · EY · contact PI
Optimizing NGF for Topical Treatment of Glaucoma$981,060
R44 · FY2023 · EY · contact PI
Optimization of TIL Cell Manufacturing for Cancer Treatment$400,000
R43 · FY2023 · CA · contact PI
tPA and NGF therapy for stroke$359,500
R43 · FY2021 · NS · contact PI
Optimizing NGF for Topical Treatment of Glaucoma$299,805
R43 · FY2017 · EY · contact PI
Recombinant Prothrombin Therapy for Hemorrhage$299,575
R43 · FY2017 · HL · contact PI